Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

BACE1 (beta-secretase) transgenic and knockout mice: identification of neurochemical deficits and behavioral changes.

Harrison SM, Harper AJ, Hawkins J, Duddy G, Grau E, Pugh PL, Winter PH, Shilliam CS, Hughes ZA, Dawson LA, Gonzalez MI, Upton N, Pangalos MN, Dingwall C.

Mol Cell Neurosci. 2003 Nov;24(3):646-55.

PMID:
14664815
2.

Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis.

Zhao J, Fu Y, Yasvoina M, Shao P, Hitt B, O'Connor T, Logan S, Maus E, Citron M, Berry R, Binder L, Vassar R.

J Neurosci. 2007 Apr 4;27(14):3639-49.

3.

Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1.

Ohno M, Chang L, Tseng W, Oakley H, Citron M, Klein WL, Vassar R, Disterhoft JF.

Eur J Neurosci. 2006 Jan;23(1):251-60.

PMID:
16420434
4.

Astrocytic expression of the Alzheimer's disease beta-secretase (BACE1) is stimulus-dependent.

Hartlage-Rübsamen M, Zeitschel U, Apelt J, Gärtner U, Franke H, Stahl T, Günther A, Schliebs R, Penkowa M, Bigl V, Rossner S.

Glia. 2003 Jan 15;41(2):169-79.

PMID:
12509807
5.

BACE1: the beta-secretase enzyme in Alzheimer's disease.

Vassar R.

J Mol Neurosci. 2004;23(1-2):105-14. Review.

PMID:
15126696
6.

Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice.

McConlogue L, Buttini M, Anderson JP, Brigham EF, Chen KS, Freedman SB, Games D, Johnson-Wood K, Lee M, Zeller M, Liu W, Motter R, Sinha S.

J Biol Chem. 2007 Sep 7;282(36):26326-34.

7.

BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease.

Ohno M, Sametsky EA, Younkin LH, Oakley H, Younkin SG, Citron M, Vassar R, Disterhoft JF.

Neuron. 2004 Jan 8;41(1):27-33.

8.

BACE1 (beta-secretase) knockout mice do not acquire compensatory gene expression changes or develop neural lesions over time.

Luo Y, Bolon B, Damore MA, Fitzpatrick D, Liu H, Zhang J, Yan Q, Vassar R, Citron M.

Neurobiol Dis. 2003 Oct;14(1):81-8.

PMID:
13678669
9.

In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1.

Sankaranarayanan S, Price EA, Wu G, Crouthamel MC, Shi XP, Tugusheva K, Tyler KX, Kahana J, Ellis J, Jin L, Steele T, Stachel S, Coburn C, Simon AJ.

J Pharmacol Exp Ther. 2008 Mar;324(3):957-69.

10.

Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation.

Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, Kha H, Zhang J, Gong Y, Martin L, Louis JC, Yan Q, Richards WG, Citron M, Vassar R.

Nat Neurosci. 2001 Mar;4(3):231-2. No abstract available.

PMID:
11224535
11.

Novel mutations introduced at the beta-site of amyloid beta protein precursor enhance the production of amyloid beta peptide by BACE1 in vitro and in cells.

Shi XP, Tugusheva K, Bruce JE, Lucka A, Chen-Dodson E, Hu B, Wu GX, Price E, Register RB, Lineberger J, Miller R, Tang MJ, Espeseth A, Kahana J, Wolfe A, Crouthamel MC, Sankaranarayanan S, Simon A, Chen L, Lai MT, Pietrak B, DiMuzio J, Li Y, Xu M, Huang Q, Garsky V, Sardana MK, Hazuda DJ.

J Alzheimers Dis. 2005 Apr;7(2):139-48; discussion 173-80.

PMID:
15851852
12.

NFkappaB-dependent control of BACE1 promoter transactivation by Abeta42.

Buggia-Prevot V, Sevalle J, Rossner S, Checler F.

J Biol Chem. 2008 Apr 11;283(15):10037-47. doi: 10.1074/jbc.M706579200.

13.

Transcriptional regulation of BACE1, the beta-amyloid precursor protein beta-secretase, by Sp1.

Christensen MA, Zhou W, Qing H, Lehman A, Philipsen S, Song W.

Mol Cell Biol. 2004 Jan;24(2):865-74.

14.

Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis.

Velliquette RA, O'Connor T, Vassar R.

J Neurosci. 2005 Nov 23;25(47):10874-83. Erratum in: J Neurosci. 2006 Feb 15;26(7):2140-2.

15.

Beta-secretase as a target for the treatment of Alzheimer's disease.

Citron M.

J Neurosci Res. 2002 Nov 1;70(3):373-9. Review.

PMID:
12391600
16.

beta-Secretase, APP and Abeta in Alzheimer's disease.

Vassar R.

Subcell Biochem. 2005;38:79-103. Review.

PMID:
15709474
17.

BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice.

Nishitomi K, Sakaguchi G, Horikoshi Y, Gray AJ, Maeda M, Hirata-Fukae C, Becker AG, Hosono M, Sakaguchi I, Minami SS, Nakajima Y, Li HF, Takeyama C, Kihara T, Ota A, Wong PC, Aisen PS, Kato A, Kinoshita N, Matsuoka Y.

J Neurochem. 2006 Dec;99(6):1555-63.

18.

Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice.

Dominguez D, Tournoy J, Hartmann D, Huth T, Cryns K, Deforce S, Serneels L, Camacho IE, Marjaux E, Craessaerts K, Roebroek AJ, Schwake M, D'Hooge R, Bach P, Kalinke U, Moechars D, Alzheimer C, Reiss K, Saftig P, De Strooper B.

J Biol Chem. 2005 Sep 2;280(35):30797-806.

19.

The transcription factor Yin Yang 1 is an activator of BACE1 expression.

Nowak K, Lange-Dohna C, Zeitschel U, Günther A, Lüscher B, Robitzki A, Perez-Polo R, Rossner S.

J Neurochem. 2006 Mar;96(6):1696-707.

20.

High beta-secretase activity elicits neurodegeneration in transgenic mice despite reductions in amyloid-beta levels: implications for the treatment of Alzheimer disease.

Rockenstein E, Mante M, Alford M, Adame A, Crews L, Hashimoto M, Esposito L, Mucke L, Masliah E.

J Biol Chem. 2005 Sep 23;280(38):32957-67.

Items per page

Supplemental Content

Support Center